Abstract 425P
Background
The obesity survival paradox refers to the unexpected association of obesity with improved cancer survival outcomes. This phenomenon has been previously reported in IO treated solid tumor malignancies. We aimed to assess the impact of obesity on clinical outcomes in patients with advanced solid tumors treated with contemporary 1L IO based therapy.
Methods
Using the International Metastatic Renal Cell Carcinoma (RCC) Database Consortium and Alberta Immunotherapy Database, patients with advanced RCC, non-small cell lung cancer (NSCLC) or melanoma treated with 1L PD-(L)1 inhibition +/- tyrosine kinase inhibitor (RCC), chemotherapy (NSCLC) or CTLA-4 inhibitor (RCC/Melanoma) were included. As has been done in other analyses in the obesity paradox field, a comparison with obese (BMI ≥ 30.0 kg/m2) vs. normal weight (BMI 18.5-24.9 kg/m2) individuals was performed. Underweight (BMI < 18.5 kg/m2) patients (to avoid cachexia as a confounder) and overweight (BMI 25.0-29.9 kg/m2) patients (to not dilute the effect of obesity) were excluded. Objective response rate (ORR), time to treatment failure (TTF) and overall survival (OS) were calculated.
Results
Of 1067 patients, 30% and 33% of patients were found to be obese and normal weight, respectively. There were more males in obese vs. normal weight patients (66% vs. 55%, p<0.01). In NSCLC, PDL-1 expression was not different (p=0.39); and in RCC, there were less IMDC intermediate/poor risk patients among obese vs. normal weight patients (81% vs. 87%, p <0.01). In melanoma, there was no difference in BRAF status (p=0.68), LDH level (p=0.32), or metastatic burden (p=0.81) between obese vs. overweight patients. Overall, obese patients experienced a superior OS compared to normal weight patients (Table). Changing the BMI threshold to compare BMI ≥ 25 kg/m2 vs. normal weight yielded a similar result (median OS of 31.6 vs. 21.8 mons, p <0.01, respectively). Subgroup analysis by tumor type showed that the observed benefit was primarily driven by NSCLC. We were unable to detect a significant difference in OS among obese vs. normal weight patients with RCC or melanoma. In the RCC subgroup, there was a higher response rate in obese patients compared to normal weight patients. Table: 425P
Clinical outcomes of patients with obesity vs normal weight
Clinical outcome | Obesity | Normal weight | P-value |
Overall cohort (N=669) | N=316 | N=353 | - |
ORR %, (n/n) | 47% (125/265) | 40% (107/271) | 0.07 |
mTTF (mon) (95% CI) | 6.0 (4.9-7.5) | 4.8 (3.5-7.4) | 0.41 |
mOS (mon) (95% CI) | 32.2 (25.1-53.4) | 21.8 (16.3-28.1)) | 0.01 |
RCC (N=250) | N=140 | N=110 | - |
ORR | 47% (58/123) | 31% (28/90) | 0.02 |
mTTF | 7.6 (6.0-11.0) | 6.8 (3.0-9.6) | 0.86 |
mOS | 47.8 (29.6-57.8) | 30.9 (20.0-41.4) | 0.41 |
NSCLC (N=238) | N=84 | N=154 | - |
ORR | 35% (24/69) | 34% (38/112) | 0.90 |
mTTF | 5.8 (3.6-11.3) | 3.7 (2.7-4.9) | 0.20 |
mOS | 24.8 (18.5-28.3) | 8.6 (6.4-20.4) | 0.02 |
Melanoma (N=181) | N=92 | N=89 | - |
ORR | 59% (43/73) | 59% (41/69) | 0.95 |
mTTF | 4.6 (3.2-5.7) | 6.9 (2.9-10.8) | 0.48 |
mOS | 22.2 (13.0-NR) | 26.9 (18.9-NR) | 0.62 |
mTTF=median TTF, mOS=median OS
Conclusions
The obesity paradox exists in NSCLC. We are unable to demonstrate this finding in RCC, although the response rate was higher in obese patients. In melanoma, there was no difference in outcomes among obese vs. normal weight patients. The effect of obesity on treatment outcomes may be dependent on primary tumor type.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Daniel Y.C. Heng.
Funding
Has not received any funding.
Disclosure
J.C. Wells: Travel/Accommodation/Expenses: Pfizer. S.K. Pal: Advisory/Consultancy: Pfizer, Novartis, Aveo, Myriad Pharmaceuticals, Genentech, Exelixis, Bristol-Myers Squibb, Astellas Pharma, Ipsen, Eisai; Honoraria (self): Novartis, Medivation, Astellas Pharma; Research grant/Funding (institution): Medivation. F. Donskov: Research grant/Funding (institution): Pfizer, Ipsen. T.K. Choueiri: Advisory/Consultancy: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol-Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, Cerulean Pharma, AstraZeneca, Prometheus Laboratories, Alligent, Ipsen, Corvus Pharmaceuticals, Lpath, Alexion Pharmaceuticals, Sanofi/Aven; Leadership role: Dana Farber Cancer Hospital, NCCN, Kidney Cancer Association, KidneyCan, ASCO; Shareholder/Stockholder/Stock options: Pionyr, Tempest Therapeutics; Honoraria (institution): NCCN, UpToDate, Michael J. Hennessy Associates, ASCO, Harborside Press, Analysis Group, AstraZeneca, Alexion Pharmaceuticals, Sanofi/Aventis, Bayer, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Peloton Therapeutics, Pfizer, Cor; Research grant/Funding (institution): Pfizer, Novartis, Merck, Exelixis, Tracon Pharma, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, Peleton Therapeutics, Roche/Genentech, Celldex, Agensys, Eisai, Takeda, Prometheus, Ipsen, Corvus Phaarmaceuticals, Cerulean Pharma, Seatlle Genetics/Ast; Speaker Bureau/Expert testimony: Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel. D.Y.C. Heng: Advisory/Consultancy: Pfizer, Novartis, Bristol-Myers Squibb, Janssen, Astellas Pharma, Ipsen, Eisai, Merck; Research grant/Funding (institution): Pfizer, Novartis, Exelixis, Bristol-Myers Squibb, Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session